Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Given Average Recommendation of “Hold” by Analysts

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) has been assigned an average recommendation of “Hold” from the seven ratings firms that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, four have given a hold recommendation and two have given a buy recommendation to the company. The average 1-year price target among brokers that have covered the stock in the last year is $3.75.

HOWL has been the topic of several research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Werewolf Therapeutics in a research note on Monday, April 20th. Wall Street Zen raised Werewolf Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, April 7th.

Werewolf Therapeutics Stock Up 0.5%

Shares of HOWL stock opened at $0.72 on Friday. The firm has a market cap of $35.14 million, a P/E ratio of -0.53 and a beta of 0.41. The company has a 50 day moving average of $0.81 and a 200-day moving average of $0.88. Werewolf Therapeutics has a 12-month low of $0.53 and a 12-month high of $2.38.

Werewolf Therapeutics (NASDAQ:HOWL) last posted its quarterly earnings data on Friday, March 27th. The company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.34) by $0.14. As a group, equities analysts expect that Werewolf Therapeutics will post -1.29 EPS for the current year.

Insiders Place Their Bets

In other Werewolf Therapeutics news, Director Luke Evnin sold 95,412 shares of the stock in a transaction dated Tuesday, April 28th. The shares were sold at an average price of $0.73, for a total transaction of $69,650.76. Following the completion of the transaction, the director owned 2,010,508 shares in the company, valued at $1,467,670.84. This trade represents a 4.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 205,911 shares of company stock worth $154,525 in the last three months. 23.60% of the stock is owned by company insiders.

Institutional Trading of Werewolf Therapeutics

Institutional investors have recently modified their holdings of the business. Regal Investment Advisors LLC boosted its holdings in Werewolf Therapeutics by 93.3% in the 4th quarter. Regal Investment Advisors LLC now owns 52,593 shares of the company’s stock worth $33,000 after buying an additional 25,389 shares during the period. Vontobel Holding Ltd. raised its holdings in Werewolf Therapeutics by 66.7% during the 4th quarter. Vontobel Holding Ltd. now owns 60,003 shares of the company’s stock valued at $38,000 after acquiring an additional 24,003 shares during the period. Qube Research & Technologies Ltd purchased a new stake in shares of Werewolf Therapeutics during the second quarter worth $48,000. AQR Capital Management LLC purchased a new stake in shares of Werewolf Therapeutics during the first quarter worth $79,000. Finally, Bridgeway Capital Management LLC boosted its holdings in shares of Werewolf Therapeutics by 157.7% in the second quarter. Bridgeway Capital Management LLC now owns 102,000 shares of the company’s stock worth $111,000 after acquiring an additional 62,414 shares during the period. 64.84% of the stock is currently owned by hedge funds and other institutional investors.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.